삼성서울병원

Ko En

혈액종양내과 안명주 교수

진료분야
폐암, 두경부암, 식도암
진료일정 07 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후
진료일정 08 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후

학력

학력
1992.02 한양대학교 의과대학 박사 학위취득
1988.02 한양대학교 의과대학 석사 학위취득
1985.02 한양대학교 의과대학 졸업
1979.02 예일여자 고등학교 졸업

경력

경력
2007.04 ~현재 삼성서울병원 혈액종양내과 교수
2013.08 ~ 2015.03 삼성서울병원 혈액종양내과 과장
2006.02 ~ 2007.03 삼성서울병원 혈액종양내과 부교수
2005.03 ~ 2006.01 한양대학부속 서울병원 혈액종양내과 교수, 조혈모세포이식센타소장
2000.03 ~ 2005.02 한양대학부속 서울병원 혈액종양내과 부교수, 조혈모세포이식센타소장
1995.03 ~ 2000.02 한양대학부속 구리병원 혈액종양내과장 조교수
1993.03 ~ 1995.02 미국 뉴욕 Memorial Sloan Kettering Cancer Center Postdoctoral fellowship
1991.03 ~ 1993.02 서울아산병원 혈액종양전임의
1986.03 ~ 1988.02 한양대학부속병원 내과 전공의
1985.03 ~ 1986.02 한양대학부속병원 인턴

학회활동

학회활동
미국암학회 정회원
미국 암연구 학회 정회원
세계폐암학회 정회원
유럽암학회 정회원
대한두경부암학회 정회원
대한내과학회 정회원
대한의학회 정회원
대한암학회 정회원
한국임상암학회 정회원
대한폐암학회 정회원
  • J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component Yang JC11, Ahn MJ1, Kim DW1, Ramalingam SS1, Sequist LV1, Su WC1, Kim SW1, Kim JH1, Planchard D1, Felip E1, Blackhall F1, Haggstrom D1, Yoh K1, Novello S1, Gold K1, Hirashima T1, Lin CC1, Mann H1, Cantarini M1, Ghiorghiu S1, Janne PA1.
    View PubMed
  • Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. EGFR TKI combination with immunotherapy in non-small cell lung cancer Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
    View PubMed
  • Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial Hui R11, Garon EB2, Goldman JW2, Leighl NB3, Hellmann MD4, Patnaik A5, Gandhi L6, Eder JP7, Ahn MJ8, Horn L9, Felip E10, Carcereny E11, Rangwala R12, Lubiniecki GM12, Zhang J12, Emancipator K12, Roach C13, Rizvi NA14.
    View PubMed
  • Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Drilon A11, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.
    View PubMed
  • Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types Kim JE11, Jang JS2, Kim JW3, Sung YL4, Cho CH5, Lee MA6, Kim DJ7, Ahn MJ8, Lee KY9, Sym SJ10, Lim MC11, Jung H12, Cho EK12, Min KW12.
    View PubMed
  • Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. Osimertinib for the treatment of non-small cell lung cancer Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
    View PubMed
  • Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) Kim HR11, Jang JS2, Sun JM3, Ahn MJ3, Kim DW4, Jung I5, Lee KH6, Kim JH1, Lee DH7, Kim SW, Cho BC1.
    View PubMed
  • RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015 A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K
    View PubMed
  • N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer Mok TS11, Wu Y-L1, Ahn M-J1, Garassino MC1, Kim HR1, Ramalingam SS1, Shepherd FA1, He Y1, Akamatsu H1, Theelen WS1, Lee CK1, Sebastian M1, Templeton A1, Mann H1, Marotti M1, Ghiorghiu S1, Papadimitrakopoulou VA1; AURA3 Investigators.
    View PubMed
  • Pathol Res Pract. 2017 Feb;213(2):106-112. doi: 10.1016/j.prp.2016.11.012. Epub 2016 Nov 15. Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature Kwon AY11, Han J2, Chu J1, Choi YS3, Jeong BH4, Ahn MJ5, Ahn YC6.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3542-3552. doi: 10.18632/oncotarget.12200. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery Cho WK11, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.
    View PubMed
  • J Stroke. 2017 Jan;19(1):77-87. doi: 10.5853/jos.2016.00570. Epub 2016 Dec 12. Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study Lee MJ11, Chung JW1, Ahn MJ2, Kim S3, Seok JM1, Jang HM1, Kim GM1, Chung CS1, Lee KH1, Bang OY1.
    View PubMed
  • Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations Leighl NB11, Rizvi NA2, de Lima LG Jr3, Arpornwirat W4, Rudin CM5, Chiappori AA6, Ahn MJ7, Chow LQ8, Bazhenova L9, Dechaphunkul A10, Sunpaweravong P11, Eaton K12, Chen J13, Medley S13, Poondru S13, Singh M13, Steinberg J13, Juergens RA14, Gadgeel SM15.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
    View PubMed
  • Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial Hanna NH11, Kaiser R2, Sullivan RN3, Aren OR4, Ahn MJ5, Tiangco B6, Voccia I7, Pawel JV8, Kovcin V9, Agulnik J10, Gaschler-Markefski B11, Barrueco J12, Sikken P11, Schloss C12, Kim JH13; LUME-Lung 2 Study group.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14. Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease? Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.
    View PubMed
  • Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ajco.12513. Epub 2016 Jun 17. An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer Wang L11, Wu YL2, Lu S3, Deng L1, Ahn MJ4, Hsu FM5, Iscoe N6,7, Hossain A8, Puri T9, Zhang P10, Orlando M11.
    View PubMed
  • Sci Transl Med. 2016 Dec 7;8(368):368ra172. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases Yang Z11, Guo Q1, Wang Y1, Chen K1, Zhang L1, Cheng Z1, Xu Y1, Yin X1, Bai Y1, Rabbie S2, Kim DW3, Ahn MJ4, Yang JC5, Zhang X6.
    View PubMed
  • BRITISH JOURNAL OF RADIOLOGY, 2016, 89(1067), DOI: 10.1259/bjr.20160109 Value of F-18-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence Moon SH1, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, Kim BT, Lee KH
    View PubMed
  • J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations Cha YK11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.
    View PubMed
  • World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24. Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer Choi JW11, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.
    View PubMed
  • Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
    View PubMed
  • TRANSLATIONAL CANCER RESEARCH, OCT 2016, 5:S629-S631, DOI: 10.21037/tcr.2016.10.40 Liquid biopsy in non-small cell lung cancer: come of age 1,Ahn MJ
    View PubMed
  • Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor Moon SH11, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.
    View PubMed
  • Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
    View PubMed
  • Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 Crino L11, Ahn MJ2, De Marinis F2, Groen HJ2, Wakelee H2, Hida T2, Mok T2, Spigel D2, Felip E2, Nishio M2, Scagliotti G2, Branle F2, Emeremni C2, Quadrigli M2, Zhang J2, Shaw AT2.
    View PubMed
  • PLoS One. 2016 Jul 18;11(7):e0159170. doi: 10.1371/journal.pone.0159170. eCollection 2016. Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study Bang OY11,2, Chung JW1,2, Lee MJ1, Kim SJ1, Cho YH2,3, Kim GM1, Chung CS1, Lee KH1, Ahn MJ4, Moon GJ2,3.
    View PubMed
  • Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904. Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium) Lim SM11,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.
    View PubMed
  • Lung Cancer. 2016 Jun;96:56-62. doi: 10.1016/j.lungcan.2016.03.016. Epub 2016 Mar 29. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease Kim HK11, Cho JH1, Choi YS1, Zo JI1, Shim YM1, Park K2, Ahn MJ2, Ahn YC3, Kim K4, Kim J5.
    View PubMed
  • Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
    View PubMed
  • Head Neck. 2016 Apr;38 Suppl 1:E293-9. doi: 10.1002/hed.23988. Epub 2015 Jun 26. Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy Chang JH11,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15. Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14. Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial Kang JH11, Ahn MJ2, Kim DW3, Cho EK4, Kim JH5, Shin SW6, Wang X7, Kim JS8, Orlando M9, Park K2.
    View PubMed
  • Lancet. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Herbst RS11, Baas P2, Kim DW3, Felip E4, Perez-Gracia JL5, Han JY6, Molina J7, Kim JH8, Arvis CD9, Ahn MJ10, Majem M11, Fidler MJ12, de Castro G Jr13, Garrido M14, Lubiniecki GM15, Shentu Y15, Im E15, Dolled-Filhart M15, Garon EB16.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation Kim N11,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    View PubMed
  • EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652 Pembrolizumab for the treatment of non-small cell lung cancer Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
    View PubMed
  • Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study Lee JH11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.
    View PubMed
  • J Clin Oncol. 2016 Feb 10;34(5):511-2. doi: 10.1200/JCO.2015.64.2496. Epub 2015 Dec 28. Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open Reply Giovannetti E11, Zucali PA2, Rolfo C3, Assaraf YG4, Peters GJ5.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
    View PubMed
  • Oral Oncol. 2016 Feb;53:10-6. doi: 10.1016/j.oraloncology.2015.11.019. Epub 2015 Dec 19. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review Ahn MJ11, D'Cruz A2, Vermorken JB3, Chen JP4, Chitapanarux I5, Dang HQ6, Guminski A7, Kannarunimit D8, Lin TY9, Ng WT10, Park KU11, Chan AT12.
    View PubMed
  • Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02) Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.
    View PubMed
  • Jpn J Clin Oncol. 2016 Jan;46(1):40-5. doi: 10.1093/jjco/hyv163. Epub 2015 Nov 10. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy Lim SH11, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.
    View PubMed
  • Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer Lim SH11, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2. Current Status and Challenges of Cancer Clinical Trials in Korea Shim BY11, Park SH2, Lee S3, Kim JS4, Lee KE5, Kang YK6, Ahn MJ2.
    View PubMed
  • Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck Huang KK11,2, Jang KW3, Kim S4, Kim HS5,6, Kim SM3, Kwon HJ7, Kim HR7, Yun HJ8, Ahn MJ9, Park KU10, Ramnarayanan K2, McPherson JR2,11, Zhang S2, Rhee JK12, Vettore AL2, Das K2, Ishimoto T2, Kim JH5, Koh YW13, Kim SH13, Choi EC13, Teh BT1,2,14, Rozen SG2,11, Kim TM12, Tan P1,2,15, Cho BC5.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
    View PubMed
  • Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma Kim HS11, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.
    View PubMed
  • J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15. Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer Cho KR11, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.
    View PubMed
  • Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.
    View PubMed
  • Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study) Yoshioka H11, Azuma K2, Yamamoto N3, Takahashi T4, Nishio M5, Katakami N6, Ahn MJ7, Hirashima T8, Maemondo M9, Kim SW10, Kurosaki M11, Akinaga S11, Park K7, Tsai CM12, Tamura T13, Mitsudomi T14, Nakagawa K15.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131 Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer Park S1, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ
    View PubMed
  • AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847. Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer Hyun SH11, Ahn HK2, Ahn MJ3, Ahn YC4, Kim J5, Shim YM5, Choi JY1.
    View PubMed
  • J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial Sun JM11, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.
    View PubMed
  • PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer Ji JH11, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.
    View PubMed
  • Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial Soria JC11, Wu YL2, Nakagawa K3, Kim SW4, Yang JJ2, Ahn MJ5, Wang J6, Yang JC7, Lu Y8, Atagi S9, Ponce S10, Lee DH4, Liu Y11, Yoh K12, Zhou JY13, Shi X14, Webster A15, Jiang H14, Mok TS16.
    View PubMed
  • J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 Ahn JS11, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.
    View PubMed
  • Cancer Res Treat. 2015 Jul;47(3):424-35. doi: 10.4143/crt.2013.266. Epub 2014 Sep 15. Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT Yang JC11, Ahn MJ2, Nakagawa K3, Tamura T4, Barraclough H5, Enatsu S6, Cheng R7, Orlando M8.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test Choi MK11, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Clin Exp Otorhinolaryngol. 2015 Jun;8(2):142-8. doi: 10.3342/ceo.2015.8.2.142. Epub 2015 May 13. Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy Moon SH11, Choi JY1, Lee HJ1, Son YI2, Baek CH2, Ahn YC3, Ahn MJ4, Park K4, Kim BT1.
    View PubMed
  • J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases Costa DB11, Shaw AT2, Ou SH2, Solomon BJ2, Riely GJ2, Ahn MJ2, Zhou C2, Shreeve SM2, Selaru P2, Polli A2, Schnell P2, Wilner KD2, Wiltshire R2, Camidge DR2, Crin? L2.
    View PubMed
  • J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors Lee JY11, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Blumenschein GR Jr11, Smit EF2, Planchard D3, Kim DW4, Cadranel J5, De Pas T6, Dunphy F7, Udud K8, Ahn MJ9, Hanna NH10, Kim JH11, Mazieres J12, Kim SW13, Baas P14, Rappold E15, Redhu S15, Puski A16, Wu FS15, J?nne PA17.
    View PubMed
  • Clin Lung Cancer. 2015 May;16(3):228-36. doi: 10.1016/j.cllc.2014.11.002. Epub 2014 Nov 18. Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy Cha YK11, Lee HY2, Ahn MJ3, Choi YL4, Lee JH1, Park K3, Lee KS1.
    View PubMed
  • N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer Garon EB11, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.
    View PubMed
  • Head Neck. 2015 May;37(5):E66-9. doi: 10.1002/hed.23884. Epub 2015 Mar 29. Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series Kim SM11, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.
    View PubMed
  • Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer Lim SH11, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.
    View PubMed
  • N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817. AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer Janne PA11, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.
    View PubMed
  • World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.
    View PubMed
  • Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients Woo HI11, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.
    View PubMed
  • Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea Baek JH11, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.
    View PubMed
  • J Thorac Oncol. 2015 Feb;10(2):331-7. doi: 10.1097/JTO.0000000000000388. Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer Um SW11, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.
    View PubMed
  • Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25. BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer Ku BM11, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Kim HS11, Kwon HJ2, Jung I3, Yun MR4, Ahn MJ5, Kang BW6, Sun JM5, Kim SB7, Yoon DH7, Park KU8, Lee SH9, Koh YW10, Kim SH10, Choi EC10, Koo DH11, Sohn JH12, Kim B13, Kwon NJ14, Yun HJ15, Lee MG16, Lee JH17, Kim TM18, Kim HR19, Kim JH19, Paik S20, Cho BC21.
    View PubMed
  • Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing Sun JM11, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.
    View PubMed
  • J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275. Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial Park K11, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.
    View PubMed
  • J Transl Med. 2014 Oct 25;12:299. doi: 10.1186/s12967-014-0299-6. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma Ku BM1, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.
    View PubMed
  • Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial Yang JC11, Kang JH2, Mok T3, Ahn MJ4, Srimuninnimit V5, Lin CC1, Kim DW6, Tsai CM7, Barraclough H8, Altug S9, Orlando M10, Park K11.
    View PubMed
  • Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27. Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR Ahn MJ11, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM1, Massey D4, Kim M5, Shi Y6, Park K7.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease Choi MK11, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.
    View PubMed
  • Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13. Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
    View PubMed
  • Cancer Chemother Pharmacol.?2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs Lee JY11,?Lim SH,?Kim M,?Kim S,?Jung HA,?Chang WJ,?Choi MK,?Hong JY,?Lee SJ,?Sun JM,?Ahn JS,?Park K,?Ahn MJ.
    View PubMed
  • Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial Barlesi F11, Scherpereel A, Gorbunova V, Gervais R, Vikstr?m A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.
    View PubMed
  • Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin Chang WJ11, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.
    View PubMed
  • J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21 Lim SH11, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • CANCER IMAGING, APR 22 2014, 14, 10.1186/1470-7330-14-2 Prognostic value of volumetric metabolic parameters measured by [F-18]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer Park1, SB, Choi, JY, Moon, SH, Yoo, J, Kim, H, Ahn, YC, Ahn, MJ, Park, K, Kim, BT
    View PubMed
  • J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10. A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer Lira ME11, Choi YL2, Lim SM3, Deng S1, Huang D1, Ozeck M1, Han J4, Jeong JY5, Shim HS5, Cho BC3, Kim J6, Ahn MJ7, Mao M8.
    View PubMed
  • PLoS One. 2014 Feb 26;9(2):e88598. doi: 10.1371/journal.pone.0088598. eCollection 2014. Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy Chong Y11, Kim JH1, Lee HY1, Ahn YC2, Lee KS1, Ahn MJ3, Kim J4, Shim YM4, Han J5, Choi YL5.
    View PubMed
  • When the Abstract Reports a Well-Tolerated Treatment, the Data Should Support It Reply
  • Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma Sun JM11, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.
    View PubMed
  • Anticancer Res. 2014 Feb;34(2):707-14. Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy Kim HK11, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J.
    View PubMed
  • Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16. Volume-based assessment by F-18-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer Hyun SH11, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.
    View PubMed
  • J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients Kim Y11, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.
    View PubMed
  • Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy Ahn JS11, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.
    View PubMed
  • Cancer Res Treat.?2013 Dec;45(4):343-8. doi: 10.4143/crt.2013.45.4.343. Epub 2013 Dec 31. Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma Lee JY11,?Lim SH1,?Lee JY1,?Kim JH1,?Choi KH1,?Park K1,?Sun JM1,?Ahn JS1,?Ahn MJ1.
    View PubMed
  • J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf. Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089) Rittmeyer A11, Gorbunova V, Vikstr?m A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.
    View PubMed
  • Anticancer Res.?2013 Nov;33(11):5127-33. High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients Maeng CH11,?Lee HY,?Kim YW,?Choi MK,?Hong JY,?Jung HA,?Lee KS,?Kim H,?Kwon OJ,?Sun JM,?Ahn JS,?Park K,?Um SW,?Ahn MJ.
    View PubMed
  • J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8. Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) Barlesi F11, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
    View PubMed
  • Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13. doi: 10.1007/s00259-013-2400-4. Epub 2013 Apr 18. Metabolic response evaluated by F-18-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy Moon SH11, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.
    View PubMed
  • Ann Oncol. 2013 Jun;24(6):1630-9. doi: 10.1093/annonc/mds649. Epub 2013 Feb 7. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-celll lung cancer Park S11, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.
    View PubMed
  • N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150036. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer 1,[No authors listed]
    View PubMed
  • Lung Cancer. 2013 Mar;79(3):300-6. doi: 10.1016/j.lungcan.2012.11.010. Epub 2012 Dec 21. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery Ahn HK11, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff. Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012 Hirsch FR11, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.
    View PubMed
  • Med Oncol. 2013 Mar;30(1):479. doi: 10.1007/s12032-013-0479-x. Epub 2013 Feb 3. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute Han B11, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21. Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors Lee SJ11, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12. Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer Lira ME11, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
    View PubMed
  • Lung Cancer. 2013 Jan;79(1):40-5. doi: 10.1016/j.lungcan.2012.10.002. Epub 2012 Oct 25. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer Lee HY11, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ.
    View PubMed
  • Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6. Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01) Sun JM11, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.
    View PubMed
  • Eur J Cancer. 2012 Nov;48(17):3198-204. doi: 10.1016/j.ejca.2012.06.009. Epub 2012 Jul 13. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01) Ji JH1; Korean Cancer Study Group (KCSG)1, Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ.
    View PubMed
  • Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation Cho SH11, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer Ahn MJ11, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.
    View PubMed
  • J Oral Pathol Med. 2012 May;41(5):415-23. doi: 10.1111/j.1600-0714.2011.01105.x. Epub 2011 Nov 14. Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland Sung JY11, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH.
    View PubMed
  • J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Han JY11, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.
    View PubMed
  • Hum Genet.?2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations Ahn MJ11,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.
    View PubMed
  • Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy Kim ST11, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. Epub 2011 May 28. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy Lee S11, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.
    View PubMed
  • Oral Oncol. 2011 Aug;47(8):714-9. doi: 10.1016/j.oraloncology.2011.06.007. Epub 2011 Jun 25. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck Sun JM11, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Aug;68(2):531-8. doi: 10.1007/s00280-010-1522-7. Epub 2010 Nov 25. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats Sun JM11, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8. Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy Sun JM11, Han J, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung?Cancer.?2011 Jul;73(1):63-9. doi: 10.1016/j.lungcan.2010.10.019. Epub 2010 Nov 18. New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy Lee HY11,?Lee KS,?Ahn MJ,?Hwang HS,?Lee JW,?Park K,?Ahn JS,?Kim TS,?Yi CA,?Chung MJ.
    View PubMed
  • Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21. doi: 10.1111/j.1743-7563.2011.01398.x. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia Chang JW11, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.
    View PubMed
  • Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33. doi: 10.1111/j.1743-7563.2011.01399.x. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan Ahn MJ11, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.
    View PubMed
  • Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes Chang GC11, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.
    View PubMed
  • J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients Sun JM11, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27. Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors Chang MH11, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Oncology. 2010;79(1-2):78-84. doi: 10.1159/000320190. Epub 2010 Nov 12. Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment Kim ST11, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14. Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy Sun JM11, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol.?2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624. Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era Ahn MJ11,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.
    View PubMed
  • Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors Sun JM11, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.
    View PubMed
  • Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy Kim ST11, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung?Cancer.?2010 May;68(2):258-63. doi: 10.1016/j.lungcan.2009.06.008. Epub 2009 Jul 9. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases Kim KH11,?Lee J,?Lee JI,?Nam do H,?Kong DS,?Ahn YC,?Park HC,?Kwon OJ,?Kim H,?Chang MH,?Yi SY,?Ji SH,?Park YH,?Ahn JS,?Park K,?Ahn MJ.
    View PubMed
  • Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748. Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray Kim HS11, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ.
    View PubMed
  • Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719. Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer Lee DH11, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.
    View PubMed
  • APMIS.?2009 Dec;117(12):861-9. doi: 10.1111/j.1600-0463.2009.02545.x. Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer Chang MH11,?Lee J,?Han J,?Park YH,?Ahn JS,?Park K,?Ahn MJ.
    View PubMed
  • Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7. The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma Hong JY11, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.
    View PubMed
  • J Biol Chem. 2009 Jul 24;284(30):20099-110. doi: 10.1074/jbc.M109.010017. Epub 2009 Jun 1. House Dust Mite Allergen Der f 2-induced Phospholipase D1 Activation Is Critical for the Production of Interleukin-13 through Activating Transcription Factor-2 Activation in Human Bronchial Epithelial Cells Park SY11, Cho JH, Oh DY, Park JW, Ahn MJ, Han JS, Oh JW.
    View PubMed
  • J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4. Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer Park S11, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Janne PA, Ahn MJ.
    View PubMed
  • Anticancer Res. 2009 May;29(5):1817-22. Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung Kim Y11, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.
    View PubMed
  • Cancer.?2009 Apr 1;115(7):1518-30. doi: 10.1002/cncr.24151. Prognostic Model to Predict Outcomes in Nonsmall Cell Lung Cancer Patients Treated With Gefitinib as a Salvage Treatment Park MJ11,?Lee J,?Hong JY,?Choi MK,?Yi JH,?Lee SJ,?Oh SJ,?Ahn JS,?Park K,?Ahn MJ.
    View PubMed
  • Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25. Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras Kim HS11, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.
    View PubMed
  • Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy Hwang IG11, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    View PubMed
  • Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer Ahn MJ11, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Janne PA, Park K.
    View PubMed
  • APMIS. 2006 Sep;114(9):619-25. Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray Choi JH11, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY, Kim IS.
    View PubMed